← Back to Search

Integrase Inhibitor

Bictegravir + Lenacapavir for HIV

Phase 2 & 3
Recruiting
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age and body weight at screening: Cohort 1: ≥ 12 years to < 18 years weighing ≥ 35 kg, Cohort 2: ≥ 6 years to < 12 years weighing ≥ 25 kg to < 35 kg, Cohort 3: ≥ 2 years to < 6 years weighing ≥ 10 kg to < 25 kg
Documented plasma HIV-1 ribonucleic acid (RNA) levels must be < 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is < 50 copies/mL) in the last 6 months prior to screening (at least 1 measure prior to screening)
Must not have
Positive hepatitis C virus (HCV) antibody with detectable HCV RNA (participants positive for HCV antibody will have an HCV RNA test performed)
A history of or current decompensated liver cirrhosis (e.g., ascites, encephalopathy, or variceal bleeding), Current alcohol or substance use judged by the investigator to potentially interfere with the participant's study compliance
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 up to week 48, as appropriate
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to understand how safe and well-tolerated the combination drug bictegravir/lenacapavir (BIC/LEN) is in children and teenagers with HIV-1

Who is the study for?
This trial is for children and adolescents with HIV-1 who are virologically suppressed on a complex ARV regimen. It includes three age-based cohorts: 12-18 years weighing ≥35kg, 6-12 years weighing ≥25 to <35kg, and 2-6 years weighing ≥10 to <25kg. Participants must have no resistance to certain HIV medications and meet specific health criteria like adequate neutrophil count and hemoglobin levels.
What is being tested?
The study tests the safety, tolerability, and body interaction of a combined drug bictegravir/lenacapavir (BIC/LEN) in children and adolescents with stable but complex anti-HIV treatment regimens. The trial aims to confirm appropriate dosing of LEN as well as understand how BIC/LEN works over time within the body.
What are the potential side effects?
While not explicitly listed here, potential side effects may include reactions typical of antiretroviral drugs such as digestive issues, headaches, fatigue, skin rashes or allergic reactions. Specific side effects will be monitored throughout the study's duration.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My HIV-1 RNA levels have been undetectable or very low in the last 6 months.
Select...
My HIV does not have resistance to certain HIV medications.
Select...
I take more than one pill a day for HIV treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have hepatitis C with detectable virus levels.
Select...
I do not have severe liver problems or current issues with alcohol or substance use.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 up to week 48, as appropriate
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 up to week 48, as appropriate for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PK Parameter: AUCtau of BIC and LEN at Steady State
PK Parameter: Cmax of BIC and LEN at Steady State
PK Parameter: Ctrough of BIC and LEN at Steady State
Secondary study objectives
Acceptability and Palatability Summary of LEN Oral Loading Dose at Day 1 Assessed by Questionnaire
Acceptability and Palatability Summary of LEN Oral Loading Dose at Day 2 Assessed by Questionnaire
Acceptability and Palatability Summary of Oral BIC/LEN FDC at Week 24 Assessed by Questionnaire
+10 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort 3: Participants Aged ≥ 2 to < 6 years with Weight ≥ 10 kg to < 25 kgExperimental Treatment2 Interventions
All participants will receive a 2-day oral loading dose of LEN, and daily oral BIC and LEN dose starting on Day 1 through Week 48. Dose in cohort 3 to be defined. Following Week 48, participants will have an option to continue BIC/LEN in the extension period.
Group II: Cohort 2: Participants Aged ≥ 6 to < 12 years with Weight ≥ 25 kg to < 35 kgExperimental Treatment2 Interventions
All participants will receive a 2-day oral loading dose of LEN, and daily oral BIC and LEN dose starting on Day 1 through Week 48. Dose in cohort 2 to be defined. Following Week 48, participants will have an option to continue BIC/LEN in the extension period.
Group III: Cohort 1: Participants Aged ≥ 12 to < 18 years with Weight ≥ 35 kg: BIC/LEN 75/50 mg FDCExperimental Treatment2 Interventions
Participants will receive a 2-day oral loading dose of LEN (600 mg) on Days 1 and 2 and daily oral BIC/LEN 75/50 mg starting on Day 1 through Week 48. Following Week 48, participants will have an option to continue BIC/LEN in the extension period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lenacapavir
2018
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor
1,129 Previous Clinical Trials
867,437 Total Patients Enrolled
Gilead Study DirectorStudy DirectorGilead Sciences
358 Previous Clinical Trials
192,034 Total Patients Enrolled
~50 spots leftby Feb 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top